Graves disease following rabbit antithymocyte globulin treatment of severe aplastic anemia in a Korean child

다국어 초록 (Multilingual Abstract)

Antithymocyte globulin (ATG) is used as an immunosuppressive treatment (IST) to deplete clonal suppressor T cells in patients with severe aplastic anemia (SAA). The depletion of suppressor T cells by ATG may affect the activation of B cells, which results in an increased risk for autoimmune conditions. A 12-year-old boy was diagnosed with idiopathic SAA. As he did not have an human leukocyte antigen-matched sibling, he was treated with rabbit ATG (3.5 mg/kg/day for 5 days) and cyclosporine. Five months later, he became transfusion independent. However, 23 months after IST, he complained of mild hand tremors, sweating, weight loss, palpitations, and goiter. Results of thyroid function tests revealed hyperthyroidism (free thyroxine, 3.42 ng/dL; thyroid stimulating hormone [TSH], <0.01 nIU/mL; triiodothyronine, 3.99 ng/mL). Results of tests for autoantibodies were positive for the antimicrosome antibody and TSH-binding inhibitory immunoglobulin, but negative for the antithyroglobulin antibody and antinuclear antibody. He was treated with methimazole, and his symptoms improved. The patient has been disease free for 39 months after IST and 9 months after methimazole treatment. This case report suggests that although rare, rabbit ATG may have implications in the pathogenesis of autoimmune hyperthyroidism. Our findings suggest that thyroid function tests should be incorporated in the routine follow-up of SAA patients treated with ATG.

참고문헌 (Reference)

1 Volpe R., "The immunoregulatory disturbance in autoimmune thyroid disease" 2 : 55-72, 1988

2 Kumar M, "Severe aplastic anaemia and Grave's disease in a paediatric patient" 118 : 327-329, 2002

3 Zomas A, "Rapid progression of fibrosing alveolitis and thyrotoxicosis after antithymocyte globulin therapy for aplastic anemia" 71 : 49-51, 1995

4 Feng X, "Rabbit ATG but not horse ATG promotes expansion of functional CD4+CD25highFOXP3+ regulatory T cells in vitro" 111 : 3675-3683, 2008

5 Teramura M, "Mechanism of action of antithymocyte globulin in the treatment of aplastic anaemia: in vitro evidence for the presence of immunosuppressive mechanism" 96 : 80-84, 1997

6 Schroder K, "Interferon-gamma: an overview of signals, mechanisms and functions" 75 : 163-189, 2004

7 Nishikawa T, "Interferon-gamma inhibition of human thyrotropin receptor gene expression" 77 : 1084-1089, 1993

8 Yoshikawa N, "IFN-gamma has a protective role against thyroid-specific autoantibody production in severe combined immunodeficient(SCID)mice xenografted with Graves' thyroid tissue" 6 : 437-443, 1996

9 Scheinberg P, "Horse versus rabbit antithymocyte globulin in acquired aplastic anemia" 365 : 430-438, 2011

10 Todd A, "Graves' disease following successful treatment of severe aplastic anaemia with antilymphocyte globulin" 21 : 69-70, 1999

11 Killick SB, "Effects of antithymocyte globulin on bone marrow CD34+ cells in aplastic anaemia and myelodysplasia" 108 : 582-591, 2000

12 Scheinberg P, "Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anemia" 109 : 3219-3224, 2007

13 Ginsberg J., "Diagnosis and management of Graves’ disease" 168 : 575-585, 2003

14 Young NS, "Current concepts in the pathophysiology and treatment of aplastic anemia" 108 : 2509-2519, 2006

15 Hinterberger-Fischer M, "Coincidence of severe aplastic anaemia with multiple sclerosis or thyroid disorders: report of 5 cases" 92 : 136-139, 1994